Fuji Health Science, Inc., Mount Laurel, NJ announced today that its parent company, Fuji Chemical Industry Co., Ltd. has been granted U.S. Patent No. 7,078,040, which involves inhibiting the expression of inflammatory cytokines and chemokines by the administration of astaxanthin.

This new patent joins other Fuji patents for astaxanthin in areas such as muscle endurance, immunomodulation, gastric health and fertility. Fuji's pending patents for astaxanthin include the areas of eye fatigue, wrinkle reduction, weight loss, diabetic nephropathy and dyspepsia.

According to Charles DePrince, President of Fuji Health Science, Inc., "Our intellectual property is an indicator of Fuji's dedication to support the research into the benefits of astaxanthin. This support continues aggressively with our newest research involving the areas contributing to metabolic syndrome."

Fuji Chemical, producer of AstaREAL® astaxanthin, is the world's leading supplier of natural astaxanthin from the microalgae, haematococcus pluvialis. Fuji uses fully enclosed state of the art cultivation systems for astaxanthin in both Hawaii and Sweden.

For more information contact: Joseph Catalfamo
856 234 3636
[email protected]

- END -